• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Access, autonomy, and affordability: ethical and human rights issues surrounding multigene panel testing for cancer in Japan and Switzerland.
 
  • Détails
Titre

Access, autonomy, and affordability: ethical and human rights issues surrounding multigene panel testing for cancer in Japan and Switzerland.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Frontiers in Genetics  
Auteur(s)
Nakasato, K.
Auteure/Auteur
Manz, C.
Auteure/Auteur
Kato, K.
Auteure/Auteur
Liens vers les personnes
Manz, Carlotta  
Liens vers les unités
Centre droit comp. europ. internat.  
ISSN
1664-8021
Statut éditorial
Publié
Date de publication
2024
Volume
15
Première page
1343720
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Introduction: Advancements in precision medicine and genomics have led to prospects in a wide range of clinical fields, including oncology. In particular, developments in next-generation sequencing multigene panel tests have led to the possibility of tailoring treatment to the specific genomic markers of a patient's cancer. However, findings from current literature suggest that the path to implementation and uptake of genomic medicine is not without uncertainties and challenges. Methods: To better understand the current challenges to the implementation of genomic medicine services, we investigated the current state of patient access to genomic medicine in Japan and Switzerland. In this investigation, we focused on equal access, patient autonomy, and healthcare affordability. Results: Results have shown that although multigene panel testing is in principle covered by health insurance in both countries, barriers exist in terms of where the tests are available, comprehensive information for patients, and the affordability of not only the test itself but the overall process from diagnosis to treatment. Discussion: These results suggest a need to continue examining a more diverse range of clinical landscapes for genomic medicine to reveal more nuanced understandings of barriers to implementation and thus better identify best practices for overcoming them.
Sujets

Japan

Switzerland

equal access

genomic medicine

healthcare affordabil...

multigene panel testi...

patient autonomy

precision medicine

PID Serval
serval:BIB_8E6A74501D12
DOI
10.3389/fgene.2024.1343720
PMID
38343692
WOS
001157355100001
Permalien
https://iris.unil.ch/handle/iris/201356
Open Access
Oui
Date de création
2024-02-20T14:08:36.183Z
Date de création dans IRIS
2025-05-21T02:42:36Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

38343692_BIB_8E6A74501D12.pdf

Version du manuscrit

published

Licence

https://creativecommons.org/licenses/by/4.0

Taille

665.56 KB

Format

Adobe PDF

PID Serval

serval:BIB_8E6A74501D12.P001

URN

urn:nbn:ch:serval-BIB_8E6A74501D126

Somme de contrôle

(MD5):d5dc6b6922b9a82f1609432bfefa3b79

  • Copyright © 2024 UNIL
  • Informations légales